Immunohistochemical labelling for the hypoxia marker HIF-1α in clinically derived osteosarcoma tumour samples correlates with pathologic stage, and tumours from patients with medium to strong HIF-1α expression had decreases in both overall survival and disease-free survival [8]. The gene discussed is HIF1A; the disease is neoplasm.